| 焦 武,姚 峰,汪雯洁.Neo-Bioscore评分在乳腺癌新辅助化疗预后评估中的价值[J].肿瘤学杂志,2019,25(5):432-435. |
| Neo-Bioscore评分在乳腺癌新辅助化疗预后评估中的价值 |
| Neo-Bioscore System in Evaluating Prognosis of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy |
| 投稿时间：2018-04-16 |
| DOI：10.11735/j.issn.1671-170X.2019.05.B011 |
|
 |
| 中文关键词: 乳腺癌 新辅助化疗 预后评价 Neo-Bioscore评分 |
| 英文关键词:breast cancer neoadjuvant chemotherapy prognosis Neo-Bioscore scoring system |
| 基金项目:湖北省计生委科研项目（JS-2011019） |
|
| 摘要点击次数: 2447 |
| 全文下载次数: 439 |
| 中文摘要: |
| 摘 要：［目的］ 探讨Neo-Bioscore评分系统对比临床分期系统、病理分期系统以及CPS+EG评分系统在乳腺癌新辅助化疗预后评估的价值。［方法］ 收集2010年1月至2017年6月乳腺癌新辅助化疗198例患者资料，随访时间为期5年，分别通过4个不同的分期系统进行预后评估，计算5年总体生存率。 ［结果］ 全组198例患者5年总生存率为72%；不同病理分期之间生存情况存在较多的交叉(P>0.05)，而Neo-Bioscore评分系统变化区间最大（P<0.05）。Neo-Bioscore高分值（>3分）与低分值组（≤3分）组生存率比较差异有统计学意义（χ2=17.353，P<0.05）。［结论］ Neo-Bioscore分期系统显示出较好的预后评估价值，能更全面地预测乳腺癌新辅助化疗患者的预后。 |
| 英文摘要: |
| Abstract：［Objective］ To assess the application of Neo-Bioscore system in evaluating prognosis of breast cancer patients receiving neoadjuvant chemotherapy. ［Methods］ One hundred and ninety eight patients with breast cancer received neoadjuvant chemotherapy in Renmin Hospital of Wuhan University from January 2010 to June 2017. Patients were followed-up for 5 years，and the 5-year overall survival rate(OS) was calculated. The prognosis of patients was evaluated with clinical staging system，pathological staging system，CPS+EG scoring system and Neo-Bioscore system. ［Results］ The 5-year overall survival rate was 72% in these patients. Kaplan-Meier survival curve analysis showed that the Neo-Bioscore system had better prognostic stratification than other three systems. The overall survival was significant difference in high Neo-Bioscore group(>3) and low score group(≤3)（χ2=17.353，P<0.05）. ［ Conclusion］ Neo-Bioscore system shows a better prognostic value to predict the survival of breast cancer patients undergoing neoadjuvant chemotherapy. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |